Lisdexamfetamine for Binge Eating Disorder in a Patient with a Remote Stimulant Misuse History
Lisdexamfetamine is the only medication approved specifically for binge eating disorder, and it's a Schedule II stimulant. This patient's binges are real and frequent, and so is a stimulant misuse history from fifteen years ago that she has been honest about the entire time. Whether that history should close the door on the one approved option is genuinely contested.
K.W., a 41-year-old woman, has managed payroll for a regional trucking company for nine years, work she describes as the most stable thing in her life next to the fifteen years since she last used amphetamines recreationally — a period she is matter-of-fact about, not defensive, having disclosed it unprompted at her very first appointment rather than waiting to be asked. That history dates to her early twenties, a stretch of misuse tied to a demanding retail management job and a social circle that normalized it, resolved through a structured outpatient program at 26 and never revisited since, by her own report and confirmed by fifteen years of clean urine screens whenever her primary care doctor has ordered them for unrelated reasons.
What brought her in now is binge eating disorder, diagnosed six months ago after her primary care physician asked routine screening questions during a visit for hypertension management: four to five episodes a week of eating a large amount of food in a discrete period with a clear sense of loss of control, almost always at night, followed by shame rather than any compensatory behavior — no purging, no laxative use, a picture that fits the diagnosis cleanly. Six weeks of CBT-guided self-help materials have not meaningfully moved the frequency. The medication under discussion, lisdexamfetamine, is the only agent carrying an FDA indication specifically for binge eating disorder, based on two pivotal randomized trials (McElroy and colleagues, 2015) that found a significant reduction in binge days per week compared with placebo — a real, replicated effect, not a marginal one. It is also a Schedule II controlled stimulant, a prodrug converted to dextroamphetamine after oral absorption, chosen partly for that conversion step's theorized resistance to intravenous misuse. Whether fifteen years of confirmed abstinence from a different class of amphetamine use, in a different life circumstance, is close enough to "resolved" to make this medication reasonable. What complicates the answer is that binge eating disorder gives a stimulant a use her twenties never supplied: appetite suppression is not a side effect here but a reason to take more, and fifteen years of abstinence from one pattern of use says little about a pattern that did not yet exist.
Medication consultation, referred by primary care
I'd like to offer lisdexamfetamine with structured safeguards. It's the only medication with real randomized-trial evidence for binge eating disorder specifically — McElroy and colleagues' two pivotal trials found a significant, replicated reduction in binge days per week compared with placebo. K.W.'s misuse history is fifteen years resolved, confirmed by recent negative screening she didn't have to volunteer and did anyway. Standard stimulant safeguards — limited quantities, no early refills — are a real, established tool, not a theoretical one.
I don't doubt her fifteen years — that's a genuinely strong track record and I want to be clear I'm not questioning her honesty or her recovery. What I'd flag is that binge eating disorder itself introduces a use-case her original recovery never had to contend with: this drug suppresses appetite as a real pharmacologic effect, and a patient in active conflict with her own eating could find that effect appealing well beyond the binge-control indication — taking more than prescribed specifically to eat less, not to get high in the traditional sense. That's a different risk pathway than resuming her twenties-era pattern, and fifteen years of abstinence from that original pattern doesn't fully speak to a new one. I'd want to try topiramate or an SSRI first, neither of which carries any misuse potential at all.
I take the point about her corroborated history seriously — I just don't think it answers the specific new risk this particular drug's mechanism introduces for this particular diagnosis.
Both of you are debating a real and genuinely unresolved risk question, and I don't think tonight settles it either way. What I want to make sure doesn't get lost in that debate is her blood pressure — 138/86 on lisinopril, with no baseline cardiac workup beyond a normal EKG. If we do move toward a stimulant, that needs its own explicit answer regardless of which side of the misuse question the team eventually lands on: home blood pressure monitoring, a defined threshold for holding the medication, and reassessment before any dose increase. That's true whether we start lisdexamfetamine today or after a topiramate trial first.
Agreed: start topiramate first, given the genuinely open disagreement about lisdexamfetamine's misuse risk in this specific clinical picture, with home blood pressure monitoring established now regardless of which stimulant question resolves later. Lisdexamfetamine remains an explicit, named option if topiramate doesn't adequately reduce binge frequency over the next eight weeks.
Not agreed: whether K.W.'s fifteen-year, well-corroborated remission should ultimately outweigh the theoretical new-use-case concern if topiramate fails and lisdexamfetamine becomes the live question again. The Attending Psychiatrist believes the corroborated track record should carry real weight at that point; the Addiction Medicine Specialist maintains the new-use-case risk is structurally different regardless of how long the original pattern has been resolved and would want a more explicit relapse-prevention conversation with K.W. herself before prescribing, not just a monitoring plan. Left to be revisited together if and when topiramate doesn't work.
Educational content only — a composite teaching case, not a real patient encounter or a substitute for clinical guidance. About These Cases →